Novo Nordisk Pharmatech has entered into an agreement with Helm de México, which will be responsible for the distribution of Novo's Quats (synthetic molecules) in Mexico.
"We are very excited to announce the new distribution agreement between Helm de México and Novo Nordisk Pharmatech. We believe it is a mutually beneficial agreement. On the one hand, Novo Nordisk Pharmatech will gain access to Helm's extensive network of customers in the pharmaceutical/cosmetics industry along with the distribution infrastructure HELM has built in the 55 years we have been present in the Mexican market," Boy Ehlers, Managing Director of Helm de México, says in a Novo Nordisk Pharmatech press release, adding:
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from MedWatch
In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.